Welcome to CDC stacks | Old age and the quality of life. - 62388 | Public Health Reports
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Old age and the quality of life.
  • Published Date:
    Dec 1972
  • Source:
    Health Serv Rep. 87(10):919-931
  • Language:
    English
Filetype[PDF-6.47 MB]


This document cannot be previewed automatically as it exceeds 5 MB
Please click the thumbnail image to view the document.
Old age and the quality of life.
  • Supporting Files:
    No Additional Files
You May Also Like:
  1. Measuring the quality of life of the elderly in health promotion intervention clinical trials.
    Personal Author:
    Kutner, N G; Ory, M G; Baker, D I; Schechtman, K B; Hornbrook, M C; Mulrow, C D;
    Published:
    1992 Sep-Oct
    Source:
    Public Health Rep. 107(5):530-539
    Description:
    The Multicenter Trials of Frailty and Injuries: Cooperative Studies of Intervention Techniques (FICSIT) is a series of clinical trials of biomedical, behavioral, and environmental interventions to reduce the risks of frailty and injury among the elde...
    File Type:
    Filetype[PDF - 1.82 MB]
  2. Health-related quality of life in the CDC Anthrax Vaccine Adsorbed Human Clinical Trial☆
    Personal Author:
    Stewart, Brock; Rose, Charles E.; Tokars, Jerome I.; Martin, Stacey W.; Keitel, Wendy A.; Keyserling, Harry L.; Babcock, Janiine; Parker, Scott D.; Jacobson, Robert M.; Poland, Gregory A.; McNeil, Michael M.;
    Published:
    July 17 2012
    Source:
    Vaccine. 30(40):5875-5879
    Description:
    Background: : After the Department of Defense implemented a mandatory anthrax vaccination program in 1998 concerns were raised about potential long-term safety effects of the current anthrax vaccine. The CDC multicenter, randomized, double-blind, pla...
    File Type:
    Filetype[PDF - 473.96 KB]
  3. Cost-effectiveness of Human Papillomavirus Vaccination in the United States
    Personal Author:
    Chesson, Harrell W.; Ekwueme, Donatus U.; Saraiya, Mona; Markowitz, Lauri E.;
    Published:
    Feb 2008
    Source:
    Emerg Infect Dis. 14(2):244-251.
    Description:
    We describe a simplified model, based on the current economic and health effects of human papillomavirus (HPV), to estimate the cost-effectiveness of HPV vaccination of 12-year-old girls in the United States. Under base-case parameter values, the est...
    File Type:
    Filetype[PDF - 365.12 KB]
  4. Evaluating Human Papillomavirus Vaccination Programs
    Personal Author:
    Taira, Al V.; Neukermans, Christopher P.; Sanders, Gillian D.;
    Published:
    Nov 2004
    Source:
    Emerg Infect Dis. 10(11):1915-1923.
    Description:
    Human papillomavirus (HPV) has been implicated as the primary etiologic agent of cervical cancer. Potential vaccines against high-risk HPV types are in clinical trials. We evaluated vaccination programs with a vaccine against HPV-16 and HPV-18. We de...
    File Type:
    Filetype[PDF - 346.88 KB]
  5. Cost Effectiveness of a Potential Vaccine for Human papillomavirus
    Personal Author:
    Sanders, Gillian D.; Taira, Al V.;
    Published:
    Jan 2003
    Source:
    Emerg Infect Dis. 9(1):37-48.
    Description:
    Human papillomavirus (HPV) infection, usually a sexually transmitted disease, is a risk factor for cervical cancer. Given the substantial disease and death associated with HPV and cervical cancer, development of a prophylactic HPV vaccine is a public...
    File Type:
    Filetype[PDF - 389.46 KB]